Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021Esther Kissling, Mia Brytting, Itziar Casado et al.|Eurosurveillance|2021Cited by 55
Low 2018/19 vaccine effectiveness against influenza A(H3N2) among 15–64-year-olds in Europe: exploration by birth cohortEsther Kissling, Francisco Pozo, Silke Buda et al.|Eurosurveillance|2019Cited by 48
Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022Angela Rose, Patricia Bruijning‐Verhagen, Nathalie Nicolay et al.|Eurosurveillance|2023Cited by 18
Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS‐CoV‐2 Infection in Older Adults During the JN.1 Lineage‐Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023–1 March 2024Lore Merdrignac, Charlotte Lanièce Delaunay, Nuno Verdasca et al.|Influenza and Other Respiratory Viruses|2024Cited by 14
COVID-19 Vaccine Effectiveness in Autumn and Winter 2022 to 2023 Among Older EuropeansCharlotte Lanièce Delaunay, Carla López Causapé, Clara Mazagatos et al.|JAMA Network Open|2024Cited by 10